A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare 2 combination drug therapies in HIV-infected patients who have never received anti-HIV treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Glaxo Wellcome
• Treatments: Abacavir; Amprenavir; Lamivudine; Lamivudine, zidovudine drug combination; Nelfinavir; Zidovudine

Criteria

Inclusion Criteria

Patients must have:

• CD4 count > 50.

• HIV RNA > 5,000.

• No active AIDS (excluding CD4 count < 200).

• Ability to comply with dosing schedule and protocol evaluations.

Prior Medication:

Allowed:

• 3TC or any protease inhibitor, if < 1 week of therapy.

• Other nucleoside analogs, if < 4 weeks of therapy.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

• Active AIDS (not including CD4 count < 200).

• Malabsorption syndrome affecting drug absorption.

Concurrent Medication:

Excluded:

Enrollment in any other investigational drug protocol.

Prior Medication:

Excluded:

Non-nucleoside reverse transcriptase inhibitors.